CN105497485A - Chinese medicinal composition for treating systemic lupus erythematosus and preparation method thereof - Google Patents

Chinese medicinal composition for treating systemic lupus erythematosus and preparation method thereof Download PDF

Info

Publication number
CN105497485A
CN105497485A CN201511007260.2A CN201511007260A CN105497485A CN 105497485 A CN105497485 A CN 105497485A CN 201511007260 A CN201511007260 A CN 201511007260A CN 105497485 A CN105497485 A CN 105497485A
Authority
CN
China
Prior art keywords
parts
chinese medicine
lupus erythematosus
medicine composition
systemic lupus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201511007260.2A
Other languages
Chinese (zh)
Inventor
邓凤桂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GUANGDONG JUZHICHENG TECHNOLOGY Co Ltd
Original Assignee
GUANGDONG JUZHICHENG TECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GUANGDONG JUZHICHENG TECHNOLOGY Co Ltd filed Critical GUANGDONG JUZHICHENG TECHNOLOGY Co Ltd
Priority to CN201511007260.2A priority Critical patent/CN105497485A/en
Publication of CN105497485A publication Critical patent/CN105497485A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/238—Saposhnikovia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/254—Acanthopanax or Eleutherococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/35—Caprifoliaceae (Honeysuckle family)
    • A61K36/355—Lonicera (honeysuckle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/486—Millettia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/538—Schizonepeta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/62—Nymphaeaceae (Water-lily family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704—Polygonum, e.g. knotweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8967—Lilium, e.g. tiger lily or Easter lily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention belongs to the field of traditional Chinese medicine, and relates to a Chinese medicinal composition for treating systemic lupus erythematosus and a preparation method thereof. The Chinese medicinal composition is prepared from the following raw materials in parts by weight: 10-20 parts of suberect spatholobus stem, 10-18 parts of slenderstyle acanthopanax bark, 10-22 parts of red paeony root, 8-18 parts of divaricate saposhnikovia root, 8-16 parts of honeysuckle stem, 6-18 parts of semen brassicae, 6-16 parts of tribulus terrestris, 6-12 parts of polygonum hydropiper, 8-12 parts of fineleaf schizonepeta herb, 6-10 parts of lily, 8-12 parts of lotus plumule and 4-8 parts of liquoric root. The Chinese medicinal composition has the advantages of remarkable effect of adjusting T-cell subgroup activity, quick response in treatment of systemic lupus erythematosus, short course of treatment, remarkable treatment effect on angeitis, remarkable curative effect, safety, reliability and wide clinical application prospect.

Description

Chinese medicine composition of systemic lupus erythematosus and preparation method thereof
Technical field
The invention belongs to the field of Chinese medicines, particularly relate to Chinese medicine composition of a kind of systemic lupus erythematosus and preparation method thereof.
Background technology
Systemic lupus erythematosus (sle), a kind of diffusivity, systemic autoimmune diseases, mainly involve mucocutaneous, skeletal muscle, kidney and central nervous system, multiple organ and the systems such as lung, heart, blood can also be involved simultaneously, show various clinical symptoms, in serum, multiple autoantibody and crucial immunological abnormality can be detected.It is careful that treatment for systemic lupus erythematosus (sle) needs, and only has radical cure systemic lupus erythematosus (sle) just can avoid complication.Wherein common with the complication of cardiovascular system.The hematological of lupus erythematosus is the most common with vasculitis, with extremity, patient often occurs that large stretch of cicatrix petechia of unknown cause is for main clinical manifestation, if do not find timely and treat and develop as one pleases, the limb end of finger tip, toe point will be caused to occur the serious consequence such as depression and ulcer necrosis.
Current Western medicine cannot effective systemic lupus erythematosus, although Western medicine can control generation and the development of disease to a certain extent, but adverse effect is obvious, after drug withdrawal, the state of an illness easily recurs, and there is more side effect, therefore, there is great demand in the Chinese medicine of people to effective systemic lupus erythematosus.
Chinese patent application 201310241251.4 discloses a kind of Chinese medicine composition being used for the treatment of systemic lupus erythematosus (sle), and this Chinese medicine composition is obtained by following raw material: Cornu Bubali 10-30 part, Radix Arnebiae (Radix Lithospermi) 10-30 part, Ramulus Euonymi 5-20 part, Mirabilitum crystallina 10-30 part, Cortex Moutan 10-40 part, Caulis Sargentodoxae 10-30 part, Fructus Kochiae 10-20 part, Rhizoma Paridis 5-10 part, Radix Rumicis Japonici are with 10-40 part and Fructus Litseae 5-20 part.This Chinese medicine composition can effectively improve lupus erythematosus patients clinical symptoms, but to merge vasculitic effect for the complication of systemic lupus erythematosus be not very remarkable.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of Chinese medicine composition of systemic lupus erythematosus, this Chinese medicine composition can the misery that causes to patient of mitigation system lupus erythematosus and complication vasculitis thereof, it is evident in efficacy, safe and reliable, has wide potential applicability in clinical practice.
Technical scheme of the present invention is:
The Chinese medicine composition of systemic lupus erythematosus, described Chinese medicine composition is made up of the raw materials of following parts by weight:
Caulis Spatholobi 10-20 part, Cortex Acanthopancis 10-18 part, Radix Paeoniae Rubra 10-22 part, Radix Saposhnikoviae 8-18 part, Caulis Lonicerae 8-16 part, Semen Sinapis Albae 6-18 part, Fructus Atriplicis Sibiricae 6-16 part, Herba Polygoni hydropiperis 6-12 part, Herba Schizonepetae 8-12 part, Bulbus Lilii 6-10 part, Plumula Nelumbinis 8-12 part and Radix Glycyrrhizae 4-8 part.
Preferably, described Chinese medicine composition is made up of the raw materials of following parts by weight: Caulis Spatholobi 10 parts, Cortex Acanthopancis 10 parts, Radix Paeoniae Rubra 10 parts, Radix Saposhnikoviae 8 parts, Caulis Lonicerae 8 parts, Semen Sinapis Albae 6 parts, Fructus Atriplicis Sibiricae 6 parts, Herba Polygoni hydropiperis 6 parts, Herba Schizonepetae 8 parts, Bulbus Lilii 6 parts, Plumula Nelumbinis 8 parts and 4 parts, Radix Glycyrrhizae.
Preferably, described Chinese medicine composition is made up of the raw materials of following parts by weight: Caulis Spatholobi 20 parts, Cortex Acanthopancis 18 parts, Radix Paeoniae Rubra 22 parts, Radix Saposhnikoviae 18 parts, Caulis Lonicerae 16 parts, Semen Sinapis Albae 18 parts, Fructus Atriplicis Sibiricae 16 parts, Herba Polygoni hydropiperis 12 parts, Herba Schizonepetae 12 parts, Bulbus Lilii 10 parts, Plumula Nelumbinis 12 parts and 8 parts, Radix Glycyrrhizae.
Preferably, described Chinese medicine composition is made up of the raw materials of following parts by weight: Caulis Spatholobi 15 parts, Cortex Acanthopancis 14 parts, Radix Paeoniae Rubra 16 parts, Radix Saposhnikoviae 12 parts, Caulis Lonicerae 12 parts, Semen Sinapis Albae 12 parts, Fructus Atriplicis Sibiricae 10 parts, Herba Polygoni hydropiperis 9 parts, Herba Schizonepetae 10 parts, Bulbus Lilii 8 parts, Plumula Nelumbinis 10 parts and 6 parts, Radix Glycyrrhizae.
Further, described Chinese medicine composition is made into powder, tablet or capsule.
Correspondingly, the preparation method of described Chinese medicine composition comprises following step:
S1: get Caulis Spatholobi, Radix Saposhnikoviae, Caulis Lonicerae, Semen Sinapis Albae, Fructus Atriplicis Sibiricae, Herba Schizonepetae and Radix Glycyrrhizae in proportion respectively, clean, crushed after being dried, merge coarse powder, adding medicinal material coarse powder gross weight 8-10 times amount volume fraction is the ethanol of 60-80%, microwave extraction 10-15 minute, microwave power is 400-600W, and Extracting temperature is 40-60 DEG C, filters and retains filtering residue, at filtrate reduced in volume to 60 DEG C, relative density is the extractum of 1.05-1.15, obtained extract A;
S2: get Cortex Acanthopancis, Radix Paeoniae Rubra, Herba Polygoni hydropiperis, Bulbus Lilii and Plumula Nelumbinis in proportion respectively, pulverize after cleaning, drying, merge coarse powder, merge with the filtering residue in S1, add the water of medical material gross weight 8-10 times amount, reflux, extract, 2-3 time, each 3-5 hour, filter, merging filtrate, at filtrate reduced in volume to 60 DEG C, relative density is the extractum of 1.05-1.15, obtained extract B;
S3: extract A and extract B are merged, mixing, spraying dry, crosses 100-200 mesh sieve by dried powder, to obtain final product.
Source, the nature and flavor of the present invention's component used, return through and effect:
Caulis Spatholobi: this product is the dry rattan of leguminous plant spatholobus suberectus (Caulis Sargentodoxae, Radix seu Caulis Verntilaginis Leiocarpae, SANYE Caulis Spatholobi, nine layers of wind); Bitter in the mouth, sweet, warm in nature; Return liver, kidney channel; Enrich blood, invigorate blood circulation, dredging collateral.
Cortex Acanthopancis: this product is the dry root bark of Araliaceae acanthopanax gracilistylus; Acrid in the mouth, hardship, warm in nature; Return liver, kidney channel; Wind-damp dispelling, invigorating the liver and kidney, bone and muscle strengthening.
Radix Paeoniae Rubra: this product is the dry root of ranunculaceae plant Radix Paeoniae or river Radix Paeoniae Rubra; Bitter in the mouth, is slightly cold; Return Liver Channel; Clearing away heat and cooling blood, eliminating stasis to stop pain.
Radix Saposhnikoviae: this product is the dry root of umbelliferae Saposhnikovia divaricata; Acrid in the mouth, sweet, warm in nature; Return bladder, liver, spleen channel; Inducing diaphoresis to dispel wind, victory is wet, relieving convulsion.
Caulis Lonicerae: this product is the dry stem branch of caprifoliaceae plant Radix Ophiopogonis; Sweet in the mouth, cold in nature; Attach to the lung and stomach meridians; Heat-clearing and toxic substances removing, dispelling wind dredging collateral.
Semen Sinapis Albae: be the seed of crucifer Caulis et Folium Sinapis albee; Acrid in the mouth, warm in nature; Enter lung, stomach warp; Promoting the circulation of QI eliminating phlegm, warming spleen and stomach for dispelling cold, removing obstruction in the collateral to relieve pain.
Fructus Atriplicis Sibiricae: this product is the dry mature fruit of zygophyllaceae plant Fructus Tribuli; Acrid in the mouth, hardship, slightly warm in nature; Return Liver Channel; Suppressing the hyperactive liver resolving depression, promoting blood circulation by removing wind, improving eyesight, antipruritic.
Herba Polygoni hydropiperis: this product is the herb of polygonaceae plant Herba Polygoni hydropiperis; Acrid in the mouth, hardship, property is put down; Return spleen, stomach, large intestine channel; The stagnant removing dampness of row, dissipating blood stasis stops blooding, dispelling wind for relieving itching, removing toxic substances.
Herba Schizonepetae: this product is the dry aerial parts of labiate Herba Schizonepetae; Acrid in the mouth, slightly warm in nature; Return lung, Liver Channel; Induce sweat loose wind, rash.
Bulbus Lilii: this product is liliaceous plant tiger lily ,the dry meat scale leaf of Bulbus Lilii or Lilium tenuifolium; Sweet in the mouth, cold in nature; GUIXIN, lung meridian; Nourishing YIN and moistening the lung, clearing away heart-fire for tranquillization.
Plumula Nelumbinis: this product is the green radicle (Plumula Nelumbinis) in the middle of the mature seed of nymphaeaceae plant lotus; Bitter in the mouth, cold in nature; GUIXIN, kidney channel; Clear away heart-fire, reduce phlegm and internal heat, hemostasis, arresting seminal emission.
Radix Glycyrrhizae: this product is the dry root of glycyrrhizic legume, Glycyrrhiza inflata Bat. or Glycyrrhiza glabra L..Sweet in the mouth, property is put down; GUIXIN, lung, spleen, stomach warp; Invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain, coordinating the actions of various ingredients in a prescription.
The compatibility analysis of Chinese prescription of the present invention:
Chinese prescription of the present invention is with Caulis Spatholobi, Cortex Acanthopancis and Radix Paeoniae Rubra for monarch drug is enriched blood, dredging collateral, clearing away heat and cooling blood; With Radix Saposhnikoviae, Caulis Lonicerae and Semen Sinapis Albae for ministerial drug, inducing diaphoresis to dispel wind, heat-clearing and toxic substances removing; With Fructus Atriplicis Sibiricae, Herba Polygoni hydropiperis, Herba Schizonepetae, Bulbus Lilii and Plumula Nelumbinis for adjuvant drug, dispelling wind for relieving itching, clearing away heart-fire for tranquillization, promoting blood circulation by removing wind; With Radix Glycyrrhizae for making medicine, the coordinating the actions of various ingredients in a prescription property of medicine, all medicines coordinates, and complements each other, synergism, can vasodilative effect, and anticoagulant, the concurrent vasculitis for systemic lupus erythematosus (sle) has significant therapeutic effect.
Compared with prior art, the present invention has following technical advantage:
(1) compared with the chemotherapeutic agent of Current therapeutic, Chinese medicine composition of the present invention is natural pure Chinese medicinal preparation, and untoward reaction and side effect significantly reduce, and Chinese medicine composition effect of the present invention is comprehensive, medication effect is better, and improves the quality of life of patient.
(2) in Chinese medicine composition of the present invention containing multi-medicament component, can effective systemic lupus erythematosus by synergism, and can significantly reduce systemic lupus erythematosus disease, the compliance of raising patient.
Detailed description of the invention
It will be understood by those skilled in the art that technology disclosed in following examples represents the technology playing good action in the practice of the invention of the present inventor's discovery.But, many changes can be made in disclosed specific embodiments, and still obtain same or analogous result, and not depart from the spirit and scope of the present invention.
embodiment 1:
The embodiment of the present invention 1 pharmaceutical composition is made up of the raw materials of following parts by weight: Caulis Spatholobi 10 parts, Cortex Acanthopancis 10 parts, Radix Paeoniae Rubra 10 parts, Radix Saposhnikoviae 8 parts, Caulis Lonicerae 8 parts, Semen Sinapis Albae 6 parts, Fructus Atriplicis Sibiricae 6 parts, Herba Polygoni hydropiperis 6 parts, Herba Schizonepetae 8 parts, Bulbus Lilii 6 parts, Plumula Nelumbinis 8 parts and 4 parts, Radix Glycyrrhizae.
Preparation method is as follows:
S1: get Caulis Spatholobi, Radix Saposhnikoviae, Caulis Lonicerae, Semen Sinapis Albae, Fructus Atriplicis Sibiricae, Herba Schizonepetae and Radix Glycyrrhizae in proportion respectively, clean, crushed after being dried, merge coarse powder, adding medicinal material coarse powder gross weight 10 times amount volume fraction is the ethanol of 75%, microwave extraction 15 minutes, microwave power is 500W, and Extracting temperature is 50 DEG C, filters and retains filtering residue, at filtrate reduced in volume to 60 DEG C, relative density is the extractum of 1.05, obtained extract A;
S2: get Cortex Acanthopancis, Radix Paeoniae Rubra, Herba Polygoni hydropiperis, Bulbus Lilii and Plumula Nelumbinis in proportion respectively, pulverize after cleaning, drying, merge coarse powder, merge with the filtering residue in S1, add the water of medical material gross weight 10 times amount, reflux, extract, 3 times, each 4 hours, filter, merging filtrate, at filtrate reduced in volume to 60 DEG C, relative density is the extractum of 1.05, obtained extract B;
S3: extract A and extract B are merged, mixing, spraying dry, crosses 200 mesh sieves by dried powder, obtain traditional Chinese medicine fine powder;
S4: add suitable adjuvant toward described traditional Chinese medicine fine powder, utilize Chinese medicine preparation technology to make capsule.
embodiment 2:
The embodiment of the present invention 2 pharmaceutical composition is made up of the raw materials of following parts by weight: Caulis Spatholobi 20 parts, Cortex Acanthopancis 18 parts, Radix Paeoniae Rubra 22 parts, Radix Saposhnikoviae 18 parts, Caulis Lonicerae 16 parts, Semen Sinapis Albae 18 parts, Fructus Atriplicis Sibiricae 16 parts, Herba Polygoni hydropiperis 12 parts, Herba Schizonepetae 12 parts, Bulbus Lilii 10 parts, Plumula Nelumbinis 12 parts and 8 parts, Radix Glycyrrhizae.
Preparation method is with embodiment 1.
embodiment 3:
The embodiment of the present invention 3 pharmaceutical composition is made up of the raw materials of following parts by weight: Caulis Spatholobi 15 parts, Cortex Acanthopancis 14 parts, Radix Paeoniae Rubra 16 parts, Radix Saposhnikoviae 12 parts, Caulis Lonicerae 12 parts, Semen Sinapis Albae 12 parts, Fructus Atriplicis Sibiricae 10 parts, Herba Polygoni hydropiperis 9 parts, Herba Schizonepetae 10 parts, Bulbus Lilii 8 parts, Plumula Nelumbinis 10 parts and 6 parts, Radix Glycyrrhizae.
Preparation method is with embodiment 1.
chinese medicine composition of the present invention is on the impact of systemic lupus erythematosus (sle) MRL/lpr mice
1. experiment material
1.1 laboratory animal
7 week age Healthy female kunming mice 10,7 week age, systemic lupus erythematosus (sle) (SLE) MRL/lpr female mice 50, was provided by Guangdong Medical Lab Animal Center.
1.2 Experimental agents
(1) Chinese medicinal composition capsules for preparing of the embodiment of the present invention 1;
(2) prednisone acetate tablets (LanZhou FoCi Pharmacy Co., Ltd, the accurate word H62020884 of traditional Chinese medicines).
2. experiment grouping
7 week age, Healthy female kunming mice 10 was blank group, systemic lupus erythematosus (sle) (SLE) MRL/lpr female mice in 50 7 week age is divided into 5 groups at random, often organize 10, be respectively model group, the embodiment of the present invention 1 Chinese medicinal capsule high dose group, middle dosage group, low dose group and positive controls.After all mice adaptabilities raise one week, Chinese medicinal capsule 4.0g/kg, 2.0g/kg and 1.0g/kg that the other gavage embodiment of the present invention 1 of high, medium and low dosage component prepares; The prednisone acetate tablets (LanZhou FoCi Pharmacy Co., Ltd, the accurate word H62020884 of traditional Chinese medicines) of positive controls gavage 1.0g/kg, blank group and SLE model group are with isopyknic distilled water gavage.
All test group administration every day 1 time, successive administration 25 days, gets blood for subsequent use, wins spleen at the end of administration.
3. experimental technique and result
3.1 Chinese medicine compositions of the present invention are on the impact of SLE T lymphocyte subsets in spleen of mice immunized
The preparation of PBS liquid: take 8.5gNaCl, 0.2gKCl, 2.85gNa2HPO412H2O and 0.27gKH2PO4, with 1L distilled water standardize solution, to obtain final product;
The preparation of erythrocyte cracked liquid: take tris20.594g and be dissolved in 500-700ml distilled water, then adjust pH7.65 to 1L with 1MHCl, be mixed with tris solution; Again by 0.83%NH4Cl and tris solution in 9:1 ratio mixing after and get final product;
The preparation of Single-cell suspensions: the spleen of each group of mice is put into the culture dish filling cold PBS liquid and cleans, 3mlPBS grinding is added in glass homogenizer, filter with 200 order stainless (steel) wires again, centrifugal for Splenic vessel liquid with rotating speed 1500rpm/min centrifugal 10 minutes, abandon supernatant, and add erythrocyte cracked liquid 2.5ml, mixing, leave standstill and after 5 minutes, add PBS liquid 2ml termination lytic response again, with 1500rpm/min centrifugal 10 minutes again, abandoning supernatant, adds PBS after washing three times, under fluorescence microscope, calculate cell number with PBS.Above operation all need on ice.Use above Single-cell suspensions, after meter cell number, cell concentration is adjusted to 5 × 106cells/ml.Each group is got a wherein mouse boosting cell sample and is done subgroup analysis, and the mouse boosting cell sample of adjusted concentration is added flow cytometry dedicated pipe, and two pipes prepared by every mouse boosting cell sample, and often pipe adds sample 100 μ l.5 μ l anti-mouse fluorescent-tagged mAbs CD3(FITC are added at the first pipe containing sample dedicated pipe) and 3 μ l anti-mouse fluorescent-tagged mAbs CD4(PE), the second pipe adds 5 μ lCD3(FITC) and 3 μ l anti-mouse fluorescent-tagged mAbs CD8(PE).Room temperature black out hatches 30min, and each pipe adds 500 μ l sheath fluids, vibration mixing.Carry out upper machine analysis.Experimental result is in table 1.
Table 1 Chinese medicine composition of the present invention is on the impact of SLE T lymphocyte subsets in spleen of mice immunized
As shown in Table 1, contrast with blank group, SLE mouse model group CD3+CD4+ lymphocyte level significantly declines, and SLE mouse model group CD3+CD8+ lymphocyte level significantly rises.Contrast with SLE model group, Chinese medicine composition of the present invention and positive controls can make SLE mice CD3+CD4+T lymphocyte significantly rise, CD3+CD8+T lymphocyte is significantly declined, and wherein the middle dosage group effect of Chinese medicine composition is better, is better than positive controls.And CD3+CD4+ lymphocyte is helper T lymphocyte (Th), CD3+CD8+ lymphocyte mainly plays inhibition regulating action, and above result shows, Chinese medicine composition of the present invention can correct the imbalance state of SLE mouse T cell subgroup.
3.2 Chinese medicine compositions of the present invention are on the impact of serum IL-10, anti-ds-DNA antibody content
By the operating instruction operational approach of test kit, adopt IL-10, anti-ds-DNA antibody test kit (Shanghai Ke Feng biological reagent company limited), measure the content of each group of mice serum IL-10, anti-ds-DNA antibody, experimental result is in table 2.
Table 2 the present invention is on the impact of SLE mice serum IL-10, anti-ds-DNA antibody content
Note: compare with blank group, △ △p < 0.01, △ △ △p < 0.001; Compare with model group, *p < 0.05, *p < 0.01, * *p < 0.001; Compare with positive controls, #p < 0.05.
As shown in Table 2, compared with blank group, IL-10 and the anti-ds-DNA antibody level of SLE model mice obviously raise; Compared with SLE model group, the high, medium and low dosage group of Chinese medicine composition of the present invention and the SLE mice serum IL-10 of positive controls and anti-ds-DNA antibody level content significantly reduce, wherein very remarkable with Chinese medicine composition high dose group effect, be better than positive controls.This shows, medicine of the present invention is remarkable for SLE mice therapeutic effect.
3.3 Chinese medicine compositions of the present invention are on the impact of SLE mouse retention microalbumin content
The collection of specimen and detection: in the 20th day mice is put in metabolic cage respectively and raises, collect 12 hours overnight urine, accurate recording urine volume.After sodium azide process, centrifugal (2000r/min) 10min, measures the mice urine 2ml of storage, and each group adds bromophenol blue (0.231mmol/L) developer 1ml, and mixing (preventing bubble), measures absorbance A with ultraviolet spectrophotometer under 600nm.The content size of absorbance A reflection microdose urine protein, A value is less, and microdose urine protein content is lower.
Experimental result is in table 3.
Table 3 Chinese medicine composition of the present invention is on the impact of SLE mouse retention microalbumin content
Note: compare with blank group, △ △ △p < 0.001; Compare with model group, *p < 0.05, *p < 0.01, * *p < 0.001; Compare with positive controls, #p < 0.05.
As shown in Table 3, compared with SLE model group, the high, medium and low dosage group of pharmacy composite of the present invention and positive controls all significantly can reduce albuminous content in SLE mice urine, wherein particularly remarkable with Chinese medicine composition high dose group effect, are better than positive drug.This shows further, and Chinese medicine composition of the present invention has outstanding therapeutic effect for the damage of SLE mouse kidney.
Owing to describing the present invention by above preferred embodiment, in spirit of the present invention and/or scope, any for replacement/of the present invention or combination implement the present invention, be all apparent for a person skilled in the art, and be included among the present invention.

Claims (7)

1. the Chinese medicine composition of systemic lupus erythematosus, is characterized in that, described Chinese medicine composition is by following parts by weight
Raw materials composition:
Caulis Spatholobi 10-20 part, Cortex Acanthopancis 10-18 part, Radix Paeoniae Rubra 10-22 part, Radix Saposhnikoviae 8-18 part, Caulis Lonicerae 8-16 part, Semen Sinapis Albae 6-18 part, Fructus Atriplicis Sibiricae 6-16 part, Herba Polygoni hydropiperis 6-12 part, Herba Schizonepetae 8-12 part, Bulbus Lilii 6-10 part, Plumula Nelumbinis 8-12 part and Radix Glycyrrhizae 4-8 part.
2. the Chinese medicine composition of systemic lupus erythematosus as claimed in claim 1, is characterized in that, described Chinese drug-treated group
Compound is made up of the raw materials of following parts by weight:
Caulis Spatholobi 10 parts, Cortex Acanthopancis 10 parts, Radix Paeoniae Rubra 10 parts, Radix Saposhnikoviae 8 parts, Caulis Lonicerae 8 parts, Semen Sinapis Albae 6 parts, Fructus Atriplicis Sibiricae 6 parts, Herba Polygoni hydropiperis 6 parts, Herba Schizonepetae 8 parts, Bulbus Lilii 6 parts, Plumula Nelumbinis 8 parts and 4 parts, Radix Glycyrrhizae.
3. the Chinese medicine composition of systemic lupus erythematosus as claimed in claim 1, is characterized in that, described Chinese drug-treated group
Compound is made up of the raw materials of following parts by weight:
Caulis Spatholobi 20 parts, Cortex Acanthopancis 18 parts, Radix Paeoniae Rubra 22 parts, Radix Saposhnikoviae 18 parts, Caulis Lonicerae 16 parts, Semen Sinapis Albae 18 parts, Fructus Atriplicis Sibiricae 16 parts, Herba Polygoni hydropiperis 12 parts, Herba Schizonepetae 12 parts, Bulbus Lilii 10 parts, Plumula Nelumbinis 12 parts and 8 parts, Radix Glycyrrhizae.
4. the Chinese medicine composition of systemic lupus erythematosus as claimed in claim 1, is characterized in that, described Chinese drug-treated group
Compound is made up of the raw materials of following parts by weight:
Caulis Spatholobi 15 parts, Cortex Acanthopancis 14 parts, Radix Paeoniae Rubra 16 parts, Radix Saposhnikoviae 12 parts, Caulis Lonicerae 12 parts, Semen Sinapis Albae 12 parts, Fructus Atriplicis Sibiricae 10 parts, Herba Polygoni hydropiperis 9 parts, Herba Schizonepetae 10 parts, Bulbus Lilii 8 parts, Plumula Nelumbinis 10 parts and 6 parts, Radix Glycyrrhizae.
5. the Chinese medicine composition of the systemic lupus erythematosus as described in as arbitrary in claim 1-4, is characterized in that, described
The preparation method of Chinese medicine composition comprises following step:
S1: get Caulis Spatholobi, Radix Saposhnikoviae, Caulis Lonicerae, Semen Sinapis Albae, Fructus Atriplicis Sibiricae, Herba Schizonepetae and Radix Glycyrrhizae in proportion respectively, clean, crushed after being dried, merge coarse powder, adding medicinal material coarse powder gross weight 8-10 times amount volume fraction is the ethanol of 60-80%, microwave extraction 10-15 minute, microwave power is 400-600W, and Extracting temperature is 40-60 DEG C, filters and retains filtering residue, at filtrate reduced in volume to 60 DEG C, relative density is the extractum of 1.05-1.15, obtained extract A;
S2: get Cortex Acanthopancis, Radix Paeoniae Rubra, Herba Polygoni hydropiperis, Bulbus Lilii and Plumula Nelumbinis in proportion respectively, pulverize after cleaning, drying, merge coarse powder, merge with the filtering residue in S1, add the water of medical material gross weight 8-10 times amount, reflux, extract, 2-3 time, each 3-5 hour, filter, merging filtrate, at filtrate reduced in volume to 60 DEG C, relative density is the extractum of 1.05-1.15, obtained extract B;
S3: extract A and extract B are merged, mixing, spraying dry, crosses 100-200 mesh sieve by dried powder, to obtain final product.
6. the Chinese medicine composition of the systemic lupus erythematosus as described in as arbitrary in claim 1-4, it is characterized in that, described Chinese medicine composition is powder, tablet or capsule.
7. the preparation method of the Chinese medicine composition of the systemic lupus erythematosus as described in as arbitrary in claim 1-6, is characterized in that, comprise following step:
S1: get Caulis Spatholobi, Radix Saposhnikoviae, Caulis Lonicerae, Semen Sinapis Albae, Fructus Atriplicis Sibiricae, Herba Schizonepetae and Radix Glycyrrhizae in proportion respectively, clean, crushed after being dried, merge coarse powder, adding medicinal material coarse powder gross weight 8-10 times amount volume fraction is the ethanol of 60-80%, microwave extraction 10-15 minute, microwave power is 400-600W, and Extracting temperature is 40-60 DEG C, filters and retains filtering residue, at filtrate reduced in volume to 60 DEG C, relative density is the extractum of 1.05-1.15, obtained extract A;
S2: get Cortex Acanthopancis, Radix Paeoniae Rubra, Herba Polygoni hydropiperis, Bulbus Lilii and Plumula Nelumbinis in proportion respectively, pulverize after cleaning, drying, merge coarse powder, merge with the filtering residue in S1, add the water of medical material gross weight 8-10 times amount, reflux, extract, 2-3 time, each 3-5 hour, filter, merging filtrate, at filtrate reduced in volume to 60 DEG C, relative density is the extractum of 1.05-1.15, obtained extract B;
S3: extract A and extract B are merged, mixing, spraying dry, crosses 100-200 mesh sieve by dried powder, to obtain final product.
CN201511007260.2A 2015-12-30 2015-12-30 Chinese medicinal composition for treating systemic lupus erythematosus and preparation method thereof Withdrawn CN105497485A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201511007260.2A CN105497485A (en) 2015-12-30 2015-12-30 Chinese medicinal composition for treating systemic lupus erythematosus and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201511007260.2A CN105497485A (en) 2015-12-30 2015-12-30 Chinese medicinal composition for treating systemic lupus erythematosus and preparation method thereof

Publications (1)

Publication Number Publication Date
CN105497485A true CN105497485A (en) 2016-04-20

Family

ID=55706046

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201511007260.2A Withdrawn CN105497485A (en) 2015-12-30 2015-12-30 Chinese medicinal composition for treating systemic lupus erythematosus and preparation method thereof

Country Status (1)

Country Link
CN (1) CN105497485A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114642708A (en) * 2021-04-20 2022-06-21 湖北喜美药业有限公司 Oral and external traditional Chinese medicine composition for treating systemic lupus erythematosus

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114642708A (en) * 2021-04-20 2022-06-21 湖北喜美药业有限公司 Oral and external traditional Chinese medicine composition for treating systemic lupus erythematosus

Similar Documents

Publication Publication Date Title
CN112043804A (en) Dampness-resolving toxin-vanquishing granules, preparation method thereof and antiviral drug
CN104288245B (en) Anti-aging and constitutional pharmaceutical composition and preparation method thereof and detection method
CN108478731A (en) Chinese medicine preparation and Chinese medicinal capsule for treating cardiovascular stasis coronary heart disease
CN104435686A (en) Use of traditional Chinese medicine preparation in preparation of medicine for treating skin itch and eczema papulosum
CN111729054A (en) Dampness-resolving toxin-vanquishing traditional Chinese medicine composition, traditional Chinese medicine preparation, preparation method and application thereof
CN111803600A (en) Traditional Chinese medicine composition for preventing and treating non-alcoholic fatty liver disease and preparation method
CN106890275A (en) A kind of Traditional Chinese medicine compound composition of delaying chronic kidney trouble progress and its clinical practice
CN104042895A (en) Traditional Chinese medicine composition for treating systemic lupus erythematosus and use thereof
CN105497485A (en) Chinese medicinal composition for treating systemic lupus erythematosus and preparation method thereof
CN104984296A (en) Pharmaceutical composition for treating female climacteric syndrome and preparation method thereof
CN108014303A (en) A kind of Chinese medicine preparation for treating Ru Repair-in and preparation method thereof
CN104524164A (en) Traditional Chinese medicine preparation for treating pruritus and eczema papulosum and preparation method thereof
CN108079260A (en) A kind of Chinese medicine preparation for treating the proliferation of mammary gland and preparation method thereof
CN104095912B (en) Treat the preparation method of the Chinese patent drug of rheumatism bone disease
CN105250968A (en) Traditional Chinese medicine preparation for treating asthma
CN103877509B (en) A kind of medicine and its preparation method treating leukemia
CN104645080A (en) Traditional Chinese medicine preparation for treating dizziness and preparation method of traditional Chinese medicine preparation
CN108478745A (en) One seed ginseng Chinese herbaceous peony nourishing qi and blood particle Chinese medicine composition and preparation method thereof
CN104056017A (en) Traditional Chinese medicine composition for treating rheumatism and preparation method thereof
CN104758442B (en) It is a kind of to prevent and treat compound Chinese medicinal preparation of bronchial astehma and preparation method thereof
CN102861204A (en) Medicine for preventing and treating postpartum diseases of ruminants and preparation method thereof
CN109846962B (en) Traditional Chinese medicine composition for treating chronic urticaria
CN105395836A (en) Application of traditional Chinese medicine composition to preparation of medicine for treating wind-warm lung-heat disease
CN106728836B (en) Traditional Chinese medicine composition for treating infantile viral myocarditis and preparation method thereof
CN105456426A (en) Medicinal composition for treating systemic lupus erythematosus

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20160420

WW01 Invention patent application withdrawn after publication